Though unsurprisingly absent in GBM-30, which is characterized by the mesenchymal phenotype in vivo (15, 16, 26), SOX2+ cells were variable among patient-derived lines and dispersed throughout the layers of GBMO (Fig. S7a). This evidence concerns the gene SOX2 and glioblastoma.